Growth Metrics

Ultragenyx Pharmaceutical (RARE) Non Operating Income: 2016-2025

Historic Non Operating Income for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to -$1.0 million.

  • Ultragenyx Pharmaceutical's Non Operating Income fell 133.90% to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 199.17%. This contributed to the annual value of -$4.0 million for FY2024, which is 1075.96% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Non Operating Income is -$1.0 million, which was down 148.74% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Non Operating Income peaked at $3.1 million during Q3 2024, and registered a low of -$3.6 million during Q4 2024.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Non Operating Income value was -$699,000 (recorded in 2023), while the average stood at -$215,091.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Non Operating Income slumped by 1,288.06% in 2022, and later skyrocketed by 1,035.00% in 2023.
  • Ultragenyx Pharmaceutical's Non Operating Income (Quarterly) stood at -$410,000 in 2021, then skyrocketed by 143.90% to $180,000 in 2022, then surged by 1,035.00% to $2.0 million in 2023, then crashed by 276.51% to -$3.6 million in 2024, then plummeted by 133.90% to -$1.0 million in 2025.
  • Its Non Operating Income was -$1.0 million in Q3 2025, compared to $2.1 million in Q2 2025 and $837,000 in Q1 2025.